

Author Index

- Abdel-Wahab, Z., Darrow, T., Vervaert, C.E., Crowley, N.J., and Seigler, H.F.: Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody, 163
- Achiwa, K.: See Shimizu, T., 46
- Adachi, K.: See Satoh, M., 136
- Aldrich, W.A.: See Triozzi, P.L., 22
- Anton, A.R., Borkenhagen, K.B., Bryant, L.D., Poon, M.-C., and Lafreniere, R.: Morphologic, phenotypic, and cytotoxic analyses of C57BL/6 murine non-parenchymal liver cells: New evidence associating murine liver large granular lymphocytes with monocyte precursors and implications for tumor immunotherapy, 108
- Atzpodien, J., Körfer, A., Hadam, M., Schomburg, A., Menzel, T., Dallmann, I., Poliwooda, H., and Kirchner, H.: Diminished expression of interleukin-2 receptors *in vivo* after prior chemotherapy in advanced cancer patients receiving recombinant interleukin-2, 60
- Avner, B., Swindell, L., Sharp, E., Liao, S.-K., Ogden, J.R., Avner, B.P., Oldham, R.K.: Evaluation and clinical relevance of patient immune responses to intravenous therapy with murine monoclonal antibodies conjugated to Adriamycin, 14
- Avner, B.P.: See Avner, B., 14
- Barth, N.M.: See Oldham, R.K., 68; Oldham, R.K., 74
- Bartholomew, R.: See Rosenblum, M.G., 6
- Benjamin, R.S.: See Gonzalez, R., 192
- Bezwoza, W.R., Golombick, T., and Mansoor, N.: Interferon (IFN) alpha inhibits cell proliferation of UWOV₂ without down-regulation of transferrin receptors, 124
- Birch, R.: See Oldham, R.K., 68; Oldham, R.K., 74
- Borkenhagen, K.: See Lafreniere, R., 26
- Borkenhagen, K.B.: See Anton, A.R., 108
- Brown, C.H.: See Oldham, R.K., 74
- Bryant, L.D.: See Anton, A.R., 108; Lafreniere, R., 26
- Bunn, P.A., Jr.: See Gonzalez, R., 192
- Busbee, D.: See Peng, S.Y., 79
- Butler, K.: See Marshall, M.E., 170
- Carpenter, R.H.: See Kahlon, J.B., 127, 214
- Chaitchik, S.: See Merimsky, O., 34
- Cheung, L.: See Rosenblum, M.G., 6
- Cohen, R.J.: See Oldham, R.K., 68
- Cooper, M.F.: See Elmslie, R.E., 231
- Corrier, D.: See Peng, S.Y., 79
- Crowley, N.J.: See Abdel-Wahab, Z., 163
- Curtin, G.: See Peng, S.Y., 79
- Dallmann, I.: See Atzpodien, J., 60
- Darrow, T.: See Abdel-Wahab, Z., 163
- Davel, L.: See Eiján, A.M., 38
- de Lustig, E.S.: See Eiján, A.M., 38
- Dillman, R.O.: See Oldham, R.K., 68
- Dow, S.W.: See Elmslie, R.E., 231
- Dupere, S.: See Oldham, R.K., 74
- Eiján, A.M., Davel, L., Oisgold-Dagá, S., and de Lustig, E.S.: Modulation of tumor-induced angiogenesis by proteins of extracellular matrix, 38
- Elmslie, R.E., Ogilvie, G.K., Dow, S.W., Gasper, P., Hoover, E.A., Cooper, M.F., and Pearson, F.C.: Evaluation of a biologic response modifier derived from *Serratia marcescens*: effects on feline macrophages and usefulness for the prevention and treatment of viremia in feline leukemia virus-infected cats, 231
- Fried, A.: See Marshall, M.E., 170
- Gallinger, S., Papa, M.Z., Reilly, R.M., Xiang, J., Kirsh, J.C., Mullen, J.B.M., Stern, H.S., Hozumi, N., and Roder, J.C.: Comparative biodistribution and antibody-dependent cellular cytotoxicity of native and heavy chain chimeric antibody, 197
- Gasper, P.: See Elmslie, R.E., 231
- Giggleman, G.F., Jr.: See Sheets, M.A., 41
- Golombick, T.: See Bezwoza, W.R., 124
- Gonzalez, R., Salem, P., Bunn, P.A., Jr., Zukiwski, A.A., Lamb, R., Benjamin, R.S., Spittler, L., Wedel, N., and Robinson, W.A.: Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial, 192
- Gridley, D.S.: See Lau, B.H.S., 103
- Gridley, D.S., Prabhu Das, M.R., Lau, B.H.S., and Kettering, J.D.: Modulation of lymphoproliferation and oxidative burst by herpes-transformed tumors, 88
- Hadam, M.: See Atzpodien, J., 60
- Hall, J.: See Harris, C., 207
- Harris, C., Pierce, K., King, G., Yates, K.M., Hall, J., Tizard, I.: Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms, 207
- Hood, Y.: See Wiseman, C., 63
- Hoogstraten, B.: See Oldham, R.K., 74
- Hoover, E.A.: See Elmslie, R.E., 231
- Hozumi, N.: See Gallinger, S., 197
- Inagawa, H.: See Nishizawa, T., 224
- Jennings, C.D.: See Marshall, M.E., 204
- Jerry, L.M.: See Maeda, K., 95
- Kahlon, J.B., Kemp, M.C., Carpenter, R.H., McAnalley, B.H., McDaniel, H.R., and Shannon, W.M.: Inhibition of AIDS virus replication by Acemannan *in vitro*, 127
- Kahlon, J.B., Kemp, M.C., Yawei, N., Carpenter, R.H., Shannon, W.M., McAnalley, B.H.: *In vitro* evaluation of the synergistic antiviral effects of acemannan in combination with azidothymidine and acyclovir, 214
- Kemp, M.C.: See Kahlon, J.B., 127, 214
- Kennedy, P.: See Wiseman, C., 63
- Kettering, J.D.: See Gridley, D.S., 88
- King, G.: See Harris, C., 207
- Kirchner, H.: See Atzpodien, J., 60
- Kirsh, J.C.: See Gallinger, S., 197
- Körfer, A.: See Atzpodien, J., 60
- Kurimura, M.: See Shimizu, T., 46
- Lafreniere, R.: See Anton, A.R., 108; Maeda, K., 95
- Lafreniere, R., Borkenhagen, K., and Bryant, L.D.: Generation of MC-38 adenocarcinoma tumor-specific tumor infiltrating lymphocytes by murine anti-CD3 antibody and recombinant interleukin-2, 26
- Lamb, R.: See Gonzalez, R., 192
- Lau, B.H.S.: See Gridley, D.S., 88
- Lau, B.H.S., Yamasaki, T., and Gridley, D.S.: Garlic compounds modulate macrophage and T-lymphocyte functions, 103
- Liao, S.-K.: See Avner, B., 14
- Maeda, K., Lafreniere, R., McKinnon, J.G., and Jerry, L.M.: Generation of human autologous melanoma-specific cytotoxic T cells from tumor-involved lymph nodes, 95
- Maleckar, J.R.: See Oldham, R.K., 68
- Mansoor, N.: See Bezwoza, W.R., 124
- Marshall, M.E., Butler, K., and Fried, A.: Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies, 170
- Marshall, M.E., Rhoades, J.L., Mattingly, C., and Jennings, C.D.: Coumarin (1,2-benzopyrone) enhances DR and DQ antigen expressions by peripheral blood mononuclear cells *in vitro*, 204
- Mattingly, C.: See Marshall, M.E., 204
- McAnalley, B.H.: See Kahlon, J.B., 127, 214
- McDaniel, H.R.: See Kahlon, J.B., 127; Peng, S.Y., 79
- McKinnon, J.G.: See Maeda, K., 95
- Menzel, T.: See Atzpodien, J., 60
- Merimsky, O., Shneider, B.I., and Chaitchik, S.: Does vinblastine add to the potency of alpha interferon in the treatment of renal cell carcinoma?, 34
- Minor, D.R.: See Oldham, R.K., 68
- Mizuno, D.: See Satoh, M., 136
- Mizuno, D.-I.: See Nishizawa, T., 224
- Morikawa, A.: See Nishizawa, T., 224
- Mullen, J.B.M.: See Gallinger, S., 197
- Murray, J.L.: See Rosenblum, M.G., 6
- Nishizawa, T., Okutomi, T., Inagawa, H., Morioka, A., Oshima, H., Soma, G.-I., Mizuno, D.-I.: Intratumoral tumor necrosis factor induction in tumor bearing mice by exogenous/endogenous

- tumor necrosis factor therapy as compared with systemic administration of various biologic response modifiers, 224
- Norman, J.: *See* Peng, S.Y., 79
- O'Brien, R.: Fraud. Is there a deeper problem, 239
- O'Connor, T.: *See* Oldham, R.K., 74
- Ogden, J.R.: *See* Avner, B., 14
- Ogilvie, G.K.: *See* Elmslie, R.E., 231
- Ohtsuka, Y.: *See* Shimizu, T., 46
- Oisgold-Dagá, S.: *See* Eiján, A.M., 38
- Okutomi, T.: *See* Nishizawa, T., 224
- Oldham, R.K.: Cancer Research: A Public Trust, 122
- Custom-tailored drug immunoconjugates in cancer therapy, 148
- Is Informed Consent a Function of Who Pays?, 2
- Whose Rights Come First?, 58
- See also* Avner, B., 14
- Oldham, R.K., Dillman, R.O., Yannelli, J.R., Barth, N.M., Maleckar, J.R., Sferruzza, A., Cohen, R.J., Minor, D.R., Spitler, L., Birch, R., and West, W.H.: Continuous infusion Interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: A National Biotherapy Study Group trial, 68
- Oldham, R.K., Stark, J., Barth, N.M., Hoogstraten, B., Brown, C.H., O'Connor, T., Dupere, S., and Birch, R.: Continuous infusion Interleukin-2 and Cyclophosphamide as treatment of advanced cancers: A National Biotherapy Study Group trial, 74
- Oshima, H.: *See* Nishizawa, T., 224
- Papa, M.Z.: *See* Gallinger, S., 197
- Pearson, F.C.: *See* Elmslie, R.E., 231
- Peng, S.Y., Norman, J., Curtin, G., Corrier, D., McDaniel, H.R., and Busbee, D.: Decreased mortality of Norman Murine Sarcoma in mice treated with the immunomodulator, Acemannan, 79
- Pierce, K.: *See* Harris, C., 207
- Poliwoda, H.: *See* Atzpodien, J., 60
- Poon, M.-C.: *See* Anton, A.R., 108
- Prabhu Das, M.R.: *See* Gridley, D.S., 88
- Presant, C.: *See* Wiseman, C., 63
- Reilly, R.M.: *See* Gallinger, S., 197
- Rhoades, J.L.: *See* Marshall, M.E., 204
- Rifkin, R.: *See* Rosenblum, M.G., 6
- Rinehart, J.J.: *See* Triozzi, P.L., 22
- Robinson, W.A.: *See* Gonzalez, R., 192
- Roder, J.C.: *See* Gallinger, S., 197
- Rosenblum, M.G., Murray, J.L., Cheung, L., Rifkin, R., Salmon, S., and Bartholomew, R.: A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin, 6
- Salem, P.: *See* Gonzalez, R., 192
- Salmon, S.: *See* Rosenblum, M.G., 6
- Satoh, M., Adachi, K., Suda, T., Yamazaki, M., and Mizuno, D.: TNF-Driven inflammation during mouse liver regeneration after partial hepatectomy and its role in growth regulation of liver, 136
- Schomburg, A.: *See* Atzpodien, J., 60
- Seigler, H.F.: *See* Abdel-Wahab, Z., 163
- Sferruzza, A.: *See* Oldham, R.K., 68
- Shannon, W.M.: *See* Kahlon, J.B., 127, 214
- Sharp, E.: *See* Avner, B., 14
- Sheets, M.A., Unger, B.A., Giggelman, G.F., Jr., Tizard, I.R.: Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats, 41
- Shimizu, T., Ohtsuka, Y., Yanagihara, Y., Kurimura, M., Takemoto, M., Achiwa, K.: Comparison of biologic activities of synthetic lipopeptide analogs of bacterial lipoprotein in mice, 46
- Shnider, B.I.: *See* Merimsky, O., 34
- Soma, G.-I.: *See* Nishizawa, T., 224
- Spitler, L.: *See* Gonzalez, R., 192; Oldham, R.K., 68
- Stark, J.: *See* Oldham, R.K., 74
- Stern, H.S.: *See* Gallinger, S., 197
- Suda, T.: *See* Satoh, M., 136
- Swindell, L.: *See* Avner, B., 14
- Takemoto, M.: *See* Shimizu, T., 46
- Tizard, I.: *See* Harris, C., 207
- Tizard, I.R.: *See* Sheets, M.A., 41
- Triozzi, P.L., Aldrich, W.A., and Rinehart, J.J.: Human monocytes inhibit lymphokine-activated killer cell expansion *in vitro*, 22
- Unger, B.A.: *See* Sheets, M.A., 41
- Vervaert, C.E.: *See* Abdel-Wahab, Z., 163
- Wedel, N.: *See* Gonzalez, R., 192
- Weiner, L.M.: Applications of gamma-interferon in cancer therapy, 186
- West, W.H.: *See* Oldham, R.K., 68
- Wiseman, C., Hood, Y., Presant, C., and Kennedy, P.: OKT-3/Cyclophosphamide up-regulation of peripheral blood killer-lymphocyte subsets in human cancer patients, 63
- Xiang, J.: *See* Gallinger, S., 197
- Yamasaki, T.: *See* Lau, B.H.S., 103
- Yamazaki, M.: *See* Satoh, M., 136
- Yanagihara, Y.: *See* Shimizu, T., 46
- Yannelli, J.R.: *See* Oldham, R.K., 68
- Yates, K.M.: *See* Harris, C., 207
- Yawei, N.: *See* Kahlon, J.B., 214
- Zukiwski, A.A.: *See* Gonzalez, R., 192

Subject Index

- Acemannan, 41, 127, 207, 214
- Acyclovir, 214
- Adoptive immunotherapy, 95
- Adriamycin, 14
- Advanced malignancy, 170
- Alpha interferon, 34
- Angiogenesis inhibitors, 38
- Antibody-dependent cellular cytotoxicity, 197
- Antibody localization, 14
- Anti-CD3, 63
- Anti-CD3 monoclonal antibody, 68
- Antitumor activity, 46
- Antiviral, 127
- Azidothymidine, 214
- Biologic response modifier, 224
- Cancer, 74, 88
- Cancer therapy, 148
- Cats, 41, 207
- Chemiluminescence, 88
- Chemotherapy pretreatment, 60
- Chimeric antibody, 197
- Cimetidine, 170
- Colon cancer, 197
- Coumarin, 170, 204
- Cytokines, 6, 136, 231
- Cytotoxic lymphocytes, 63
- Cytotoxic T cells, 95
- Cytosin, 74
- Dog, 207
- Drug immunoconjugate, 148
- Exogenous/endogenous TNF therapy, 224
- Extracellular matrix, 38
- Feline, 231
- Feline leukemia, 41
- Fibronectin, 38
- Fibronectin-derived peptides, 38
- Gamma-interferon, 186
- Garlic, 103
- Gelonin, 6
- Growth regulation, 124
- HAMA, 14
- Hepatocytes, 136
- HIV-1, 127, 214
- Homeostasis, 136
- HSV-1, 214
- Human cancer, 63
- Human melanoma, 6
- Human tumor colony assay, 6
- IL-2 receptors, 60
- Imaging, 197
- Immune enhancement, 103
- Immune function, 74
- Immunoconjugates, 14
- Immuno modulation, 186, 204
- Immunomodulator, 79
- Immunostimulant, 41
- Immunosuppression, 88
- Immunotherapy, 163
- Immunotoxins, 6, 192
- ImuVert, 231
- Interferon α , 124
- Interleukin-2, 22, 60, 68, 74, 95
- Kupffer cells, 136
- Large granular lymphocytes, 108
- Lethal toxicity, 46
- Lymph node cells, 95
- Lymphocytes, 88
- Lymphokine-activated killer cells, 22
- Macrophages, 88, 103, 108, 231
- Malignant melanoma, 163
- Melanoma, 95, 192
- Metastases, 68, 163
- Methyl esters, 22
- Mitogenicity, 46
- Monoclonal antibody, 14, 192, 197
- Monocytes, 22, 204
- Monocytic phagocyte, 79
- Monokines, 79
- Murine monoclonal antibodies, 163
- Natural killer cells, 108
- Non-cytotoxic, 127
- Nylon wool, 22
- OKT-3, 63
- Ontogenesis, 136
- Protein fraction, 103
- Recombinant interleukin-2, 26
- Renal cell carcinoma, 34
- Sarcoma, 79
- Spontaneous neoplasm, 207
- Synthetic lipopeptide analogs, 46
- Targeted therapy, 14
- Therapeutic use, 186
- T-lymphocytes, 103
- Transferrin receptors, 124
- Tumor angiogenesis, 38
- Tumor-derived activated cells (TDAC), 68
- Tumor immunotherapy, 26
- Tumor infiltrating lymphocytes, 26
- Tumor lesion, 224
- Tumor necrosis factor, 224
- Tumor necrotizing factor, 46
- Vinblastine, 34
- Virus disease, 41